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Towards a novel small animal proton irradiation platform – the 
SIRMIO project 
Background: Precision small animal radiotherapy research is a young emerging 
field aiming to provide new experimental insights into tumour and tissue models 
in different microenvironments, to unravel the complex mechanisms of radiation 
damage in target and non-target tissues and assess the efficacy of novel 
therapeutic strategies. To this end, for photon therapy, modern small animal 
radiotherapy research platforms have been developed over the last years and are 
meanwhile commercially available. Conversely, for proton therapy, which holds 
a great potential for an even superior outcome than photon therapy, no 
commercial system exists yet.  
Material and methods: The project SIRMIO (Small Animal Proton Irradiator 
for Research in Molecular Image-guided Radiation-Oncology) aims at realizing 
and demonstrating an innovative portable prototype system for precision small 
animal proton irradiation, suitable for integration at existing clinical treatment 
facilities. The proposed design combines precise dose application with novel in-
situ multi-modal anatomical image guidance and in-vivo verification of the actual 
treatment delivery for precision small animal irradiation.  
Results and conclusions: This manuscript describes the status of the different 
components under development, featuring a dedicated beamline for degradation 
and focusing of clinical proton beams, along with novel detector systems for in-
situ imaging. The foreseen workflow includes pre-treatment proton transmission 
imaging for treatment planning and position verification, complemented by 
ultrasonic tumour localization, followed by image-guided delivery with on-site 
range verification by means of ionoacoustics (for pulsed beams) and positron-
emission-tomography (PET, for continuous beams). The proposed compact and 
cost-effective system promises to open a new era in small animal proton therapy 
research, contributing to the basic understanding of in-vivo radiation action to 
identify areas of potential breakthroughs in radiotherapy for future translation 
into innovative clinical strategies.  
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Introduction 
Over the last decade, several technological advances for millimetre-accurate delivery of 
intensity-modulated radiation along with in-room volumetric anatomical image 
guidance have enabled clinical introduction of more effective treatment schemes in 
modern external radiation therapy with photons and light ions [1]. However, biological 
understanding of the response of the microenvironment to radiation, both in terms of 
tumour and normal tissue, is still an unmet challenge, which is even more crucial for ion 
beams than for photons. In fact, compared to photons, ion beams induce another level of 
complexity due to their enhanced relative biological effectiveness (RBE). In addition to 
the remaining debated uncertainties in the clinically adopted constant (protons) and 
variable (carbon ions) RBE values, recent investigations have also highlighted that 
densely ionizing ion beams can elicit signalling pathways quite distinct from those 
involved in cell and tissue response to photons, thus opening innovative areas of 
research going beyond traditional RBE concepts [2]. Hence, new questions need to be 
answered to understand the complex response of tumour and normal tissue to light ions 
for possible future translation into clinical practice. To this end, experiments in animal 
tumour models are of paramount importance to test hypotheses, which would be 
difficult and often unethical to address at the clinical level, or inaccessible at the 
isolated cellular level. However, they require adequate platforms to accurately deliver 
therapeutic doses to a small tumour, while well sparing normal tissue.  
Over the last years, for photon therapy, several dedicated small animal radiation 
research platforms have been realized and meanwhile commercialized to provide 
precision image-guided radiotherapy conditions similar to state-of-the-art human 
treatments. This was accomplished by downscaling the geometry and energy of the 
therapeutic photon beam and equipping the irradiator with at least volumetric X-ray 
computed tomography (CT) imaging [3]. In contrast, in ion beam therapy, pre-clinical 
experiments are still predominantly carried out in the experimental rooms of the few 
available clinical facilities, without dedicated beamlines for accurate small animal 
irradiation. Here, common delivery solutions feature collimation of passively scattered 
broad beams or scanned pencil-like beams, moderated in range (i.e., penetration depth) 
by thick degraders just before entering the animal. Both methods exhibit limitations in 
terms of flexibility (for static collimation), beam intensity (due to attenuation especially 
in the collimation system), activation of the beam-shaping material (posing radiation 
protection issues) and production of secondary neutrons (which might affect biological 
outcome, due to their elevated biological effectiveness). In particular, even for state-of-
the-art pencil-beam scanning, the smallest achievable beam sizes of low energy 
uncollimated beams is still in the range of few to few tens millimetres full-width half-
maximum (FWHM), due to limitations of multiple Coulomb scattering in the upstream 
beam monitoring system and air gap between nozzle and isocentre, where irradiation 
typically takes place for optimal dosimetric conditions. For example, values around 30 
mm FWHM were reported at 50 MeV in [4,5]. Besides limitations in achievable beam 
size and quality, the positioning accuracy of the animal is commonly challenged by the 
restriction to external reference lasers and special custom-made holders, since the 
experimental rooms hosting radiobiological research typically do not include X-ray 
morphological imagers. An additional source of uncertainty stems from the frequent 
treatment planning approximation that considers small animals just as homogeneous 
water for dose calculation purposes, without using animal-specific X-ray computed 
tomography (CT) images like for patient treatment. Limited accuracy in target 
positioning and insufficient knowledge of the traversed tissue properties, especially 
their stopping power, contribute to the ion-specific problem of range uncertainty, i.e., 
the uncertainty in the knowledge of the beam stopping position, where the maximum 
therapeutic dose deposition (Bragg peak) occurs. This problem can be even more 
critical for pre-clinical research in small animal irradiation, where sharper Bragg peaks 
are typically present due to the lower beam energies and the involved reduction of  
range straggling. Therefore, the clinical infrastructures currently used for small animal 
radiation research show substantial limitations that restrict the class of viable 
experiments and raise concerns on the reliability, relevance and scalability of results 
obtained in such suboptimal irradiation conditions. To overcome this, alternative 
proposed solutions aim to utilize dedicated low energy beam accelerators, independent 
from the clinical sites [6]. In contrast, the project SIRMIO (Small Animal Proton 
Irradiator for Research in Molecular Image-guided Radiation-Oncology) proposes a 
compact design of a dedicated portable beamline equipped with novel detector 
technologies, which can be integrated in the experimental rooms of operational clinical 
facilities for precision image-guided small animal proton irradiation. This is deemed 
necessary to provide a tight connection between radiation oncologists and biologists, 
without the need of building costly dedicated beamlines or additional proton sources 
tailored to deliver beams of (sub)millimetre size for pre-clinical research.  
Material and methods 
The SIRMIO project entails several dedicated technological developments aimed at 
enabling precision image- and dose-guided small animal proton radiation research at 
experimental beamlines of clinical proton therapy facilities. The relevant components, 
illustrated in the schematics of figure 1, and the related investigations, addressed in 
synergistic work packages, are detailed in the following.   
 
Figure 1: Schematic illustration of the SIRMIO project with related work packages 
(WPs), featuring manipulation of an incoming clinical proton beam into a focused and 
energy-degraded pre-clinical beam (WP1), pre-treatment ion transmission imaging 
(WP2-a), in-vivo range verification with US/ionoacoustics (WP2-b) and PET (WP2-c), 
system integration and deployment for adaptive treatment workflows (WP3). 
Beam Degradation, Focusing and Monitoring 
Monte Carlo particle transport simulations using Geant4 (version 10.04.p02 [7]) were 
carried out in combination with beam-optics modelling based on the code elegant [8] to 
optimise the design of the SIRMIO beamline. The current layout foresees initial energy 
degradation and collimation of a 75 MeV proton beam from a clinical facility [9], 
followed by active magnetic focusing for achieving a sufficiently narrow beam at the 
focal point, where the mouse tumour is intended to be positioned. For the sake of 
simplicity and compatibility to generic experimental beamlines of proton therapy 
centres, which are often limited to fixed beams, the first version of the SIRMIO 
beamline is designed for the focusing of a fixed horizontal pencil beam, while moving 
the target for volumetric scanned beam irradiation. Since the beam characteristics need 
to be monitored after the dedicated SIRMIO beamline, close to the treatment isocentre, 
a segmented ionization chamber providing spatial profiling of the beam and total 
fluence measurement has also been developed in-house, and has been commissioned 
and characterized with 20 MeV protons in an experimental campaign at the Tandem 
accelerator of the Maier-Leibnitz laboratory Garching. 
Mouse Holder 
A prototype mouse holder system is being developed in-house to provide fixation of the 
animal in vertical position for optimal transmission imaging conditions (see next 
section). Major challenges taken into account include the biological requirements of 
sterility, anaesthetization and temperature stabilization of the mouse, along with 
minimal material budget to minimize beam broadening and degradation of transmission 
ion imaging performances, as well as to ensure acoustic coupling for ultrasound 
(US)/thermoacoustic imaging.  
Pre-Treatment Imaging 
Proton radiographic and tomographic transmission imaging can provide on-site 
anatomical information for target positioning and treatment planning, with the great 
potential to reduce range uncertainties inherent to the semi-empirical conversion of X-
ray Hounsfield units (HU) into relative (to water) stopping power (RSP). To this end, 
two proton imaging setups are being investigated, based on integration and single 
particle detection. The first concept, especially foreseen for deployment at accelerators 
with too large instantaneous beam current for single particle tracking (such as novel 
synchro-cyclotrons), relies on a large area CMOS sensor for spatially resolved energy 
loss measurements at multiple probing energies, similar to the work of [10]. The second 
concept, reported in more detail in this contribution, relies on the in-house development 
of low material budget Micromegas tracking detectors and a time projection chamber 
with Micromegas readout structure containing multiple Kapton absorbers functioning as 
range telescope. Both systems are being investigated and optimised on the basis of 
extensive Monte Carlo simulations using the FLUKA code (version 2011.2x-5, 
[11,12]). Additional imaging modalities for tumour visualization are being evaluated for 
daily treatment planning, based on either gold nanoparticles-enhanced proton imaging 
or microbubbles-enhanced US imaging. 
Treatment Planning 
Two treatment planning system (TPS) solutions are being considered, both featuring 
Monte Carlo dose calculation engines. The first one relies on the prototype proton 
RayStation of the RaySearch Laboratories AB company, for which a software license 
has been just purchased and a research collaboration agreement is being established. 
The alternative second option would be an extension of the in-house research TPS based 
on the coupling of a particle extension of the CERR (A Computational Environment for 
Radiotherapy Research) platform with a Geant4 dose calculation engine [13].  Both 
solutions should be able to import RSP maps from the proton transmission imaging, 
along with updated tumour contours from the daily image guidance for treatment 
planning shortly before start of irradiation.  
Currently, treatment planning studies are in progress with a precursor of the proton 
RayStation on the basis of X-ray cone beam computed tomography (CBCT) images 
acquired at a photon small animal radiation research platform (SARRP) at the LMU 
University Hospital for different orthotopic tumour entities, to identify more precisely 
the energy range requirements of the SIRMIO beamline.  
In-Vivo Range Verification 
Two solutions for in-vivo verification of the proton range in small animals are under 
development for application at different types of proton sources. For pulsed accelerators 
with high instantaneous beam current such as synchro-cyclotrons, sensing of the 
thermoacoustic emissions induced by the proton energy deposition (so called 
ionoacoustics [14]) is deemed an ideal solution for small animal proton range 
monitoring during irradiation. In fact, these ionoacoustic emissions, naturally enhanced 
at the Bragg peak location, are particularly favoured under the pre-clinical conditions of 
small beam size and low beam energies (i.e., sharp Bragg peaks), besides lending 
themselves to almost real-time co-registration of the Bragg peak location with the 
ultrasound images of the small animal anatomy. The main challenge is the co-
integration of ionoacoustic sensors and ultrasonic transducers, which operate in a 
different frequency range from few hundreds of kHz up to tens of MHz, respectively. 
To this end, different transducer technologies are being investigated in terms of their 
sensitivity and bandwidth, to enable optimal signal-to-noise ratio. For more generic 
application also at continuous wave cyclotrons and (slowly cycling) synchrotrons, a 
dedicated in-beam positron-emission-tomography (PET) scanner is being designed to 
measure the irradiation-induced pattern of -activity, which is correlated to the primary 
proton beam range [15]. The partial ring PET system design is being optimised in terms 
of sensitivity and spatial resolution, based on detector technologies enabling depth-of-
interaction, as developed at the collaborating National Institute of Radiological Sciences 
in Chiba, Japan (NIRS-QST, 16). In addition to range verification, the availability of an 
in-situ PET scanner could also open new opportunities for biological image guidance 
[15] in the foreseen pre-clinical experiments. Hence, integration of both 
ionoacoustics/US and PET imaging, along with the compatibility with the other 
SIRMIO components, is taken into account. 
Results  
Beam Degradation, Focusing and Monitoring 
The current beamline design features a triplet of permanent quadrupole magnets (PMQ) 
optimised for focusing 20-60 MeV proton beams at the treatment isocentre, at  
approximately 70 cm downstream of a variable energy degrader of graphite followed by 
two dynamic brass collimators to adjust the beam emittance prior to the magnets. Such a 
design is estimated to provide spot sizes smaller than 1 mm FWHM at the focal position 
at isocentre for an energy spread within 4%, with transmission up to 1% and neutron 
fluence below 10% [17]. In particular, the combination of passive and active beam 
shaping is observed to considerably improve the entrance-to-peak and plateau-to-peak 
ratios of the simulated laterally- integrated dose distributions in a water phantom, with 
respect to a collimator-only passive beam delivery (figure 2). However, further 
optimisation especially concerning the degrader material as well as the PMQ sensitivity 
to stray radiation, the beamline transmission efficiency and potentially more stringent 
low energy requirements is the subject of ongoing simulation and treatment planning 
studies, prior to finalizing the magnetic lattice design. For the beam monitor, the first 
segmented ionization chamber prototype performs as required and expected. In 
particular, the preliminary data analysis suggests achievable spatial resolution of a few 
tens of microns along with accurate (within ~1%) fluence monitoring in a wide dynamic 
range (5·105 - 1·1010 protons/s), which might be improved even further by slightly 
modifying the detector design.  
 Figure 2: Normalized 
laterally-integrated dose 
distributions from passive 
(blue) and active (red) 
designs for a 50 MeV 
beam, degraded from a 
clinical 75 MeV proton 
beam [9]. The passive 
design uses a 1 mm 
diameter hole in a 6 mm 
brass collimator placed 
10 cm upstream the isocentre. The active design is the proposed PMQ triplet beamline.  
Mouse Holder 
A first prototype system has been designed on the basis of the different specifications, 
accommodating the requirements for the foreseen biological studies, the need of 
minimal material budget as well as compatibility with the different SIRMIO 
components. The 3D model of the prototype and its first 3D printed realization for 
initial testing is presented in figure 3. Main features are the sterile separation from the 
outer environment through a thin foil along with the accommodation of anaesthesia 
equipment and integrated heating in the mouse support. The flexible and cost-effective 
design of the mouse support will be adapted in terms of material budget to the specific 
application, by either removing material in the beam path or adding specific material, 
which can act as additional range degrader or provide optimal acoustic coupling.  
 Figure 3: 3D model (top, including 
the mouse rendering from a real CBCT 
acquisition) and related 3D printed 
realization (bottom) of the mouse 
holder, with specific components 
highlighted (except the foreseen 
surrounding foil for sterile 
environment).  
 
 
 
 
 
 
 
Pre-Treatment Imaging 
For the integration detector solution featuring a CMOS-based system for energy loss 
measurement at different initial beam energies, preliminary results suggested the 
feasibility of the concept. In particular, when using multiple fan beams and small 
distances between imaged object and detector, sub-mm spatial resolution could be 
achieved [18]. Optimisation of the imaging performance is currently ongoing especially 
regarding a minimization of the imaging dose by special arrangement of the beam 
shape, reduction of the probing beam energies and inclusion of supplemental 
information by an additional detector, along with mitigation of the image quality 
degradation primarily due to scattering in the object. For the single particle tracking 
solution, MC simulations estimated a proton trajectory reconstruction accuracy better 
than 0.4 mm for a geometrically optimised tracker configuration, resulting in a spatial 
resolution of around 0.2 mm [19]. The use of 500 µm thick Kapton absorbers in the 
range telescope is expected to provide a range accuracy close to the range straggling 
limit of the considered clinical-like proton beams of 75 MeV initial energy, resulting in 
sub-1% RSP accuracy for most investigated tissue-equivalent materials. An example of 
a simulated proton CT (pCT) image is shown in figure 4, based on the expected 
performances of the proposed prototype. The feasibility of the detection concept was 
recently confirmed in first experiments with a small time projection chamber prototype  
using 22 MeV protons from the Tandem accelerator of the Maier-Leibnitz-Laboratory 
(MLL) [20], for which detailed data analysis is still ongoing. Further improvements of 
the detector performance in terms of reduced scattering and increased range resolution 
are also being evaluated, in combination with the possible usage of prior information 
from the SARRP X-ray CBCT scans, planned to be acquired to monitor tumour growth 
after implantation, prior to transfer of the animals to the proton facility for irradiation. 
 Figure 4: Example of MC 
simulated pCT image of a 
mouse, based on the expected 
realistic performance of the 
proposed single particle 
imaging system.  
 
 
 
 
 
Treatment Planning 
First treatment planning studies are being carried out with a prototype version precursor 
of the RayStation, using an idealized beam model based on quasi-monoenergetic 
proton beams between 10 MeV and 80 MeV initial energy, with Gaussian energy 
spread. Preliminary results suggest that also energies below 20 MeV might be needed 
for optimal coverage of the orthotopic tumours often implanted at shallow depth, thus 
potentially posing more stringent requirements to the SIRMIO beamline under 
development. Ongoing work aims to provide more realistic treatment plans, enabling 
the direct modelling of the SIRMIO beamline in RayStation, along with correct 
handling of the material assignment on the basis of the largely fluctuating grey values of 
the SARRP CBCT images or direct import of RSP maps from the (so far only 
simulated) pCT images.   
In-Vivo Range Verification 
Integration of ionoacoustics/US imaging in SIRMIO entails the development of 
dedicated instrumentation able to handle the different frequency range of ionoacoustics 
(reception only) and US imaging (emission/reception). To this hand, different 
transducer technologies were investigated at the pulsed low energy proton beam of the 
MLL Tandem accelerator, properly modulated in energy to provide ionoacoustic 
emissions in a broad frequency range from 50 kHz to 5 MHz, as well as at a dedicated 
optoacoustic setup tailored to mimic the major features of the proton-induced 
ionoacoustic signal. In these experiments, a customized detection system based on 
Capacitive Micromachined Ultrasonic Transducers (CMUT) developed at the 
Department of Engineering Roma Tre University (Rome, Italy) along with dedicated 
low-noise amplifier electronics were identified as promising candidate for the 
development of bi-modality ultrasound systems, as required for co-registration of 
ionoacoustic and US imaging [21]. Additional data acquired with special phantoms 
featuring the presence of tissue heterogeneities and microbubble ultrasound contrast 
agent are being analysed to assess their influence on the ionoacoustic signal and to 
optimise the Bragg peak position reconstruction accuracy, along with first tests of 
ionoacoustics/US co-registration. 
For the in-beam PET scanner, different detector solutions and geometrical 
configurations have been studied especially in terms of system detection efficiency and 
spatial resolution, seeking for an optimum compromise within the given space 
constraints for compatibility with the components of the SIRMIO beamline / beam 
monitor, the movable mouse holder and the integration of US/ionoacoustics. The 
current design features double-focused trapezoid-like detectors of LYSO with depth-of-
interaction (according to technology developed at NIRS-QST, [16]) and optional TOF 
capability, promising point source resolution of 0.4 – 1.0 mm (FWHM) and detection 
efficiency from 10% to 5% in the relevant few centimetres around the centre of the 
scanner field of view, where the tumour will be located (figure 5).   
 Figure 5: Schematic drawing of the 
dedicated in-beam PET scanner design for 
SIRMIO, with the mouse holder indicated by 
the red cylinder.  
 
 
 
 
 
 
 
Discussion 
The 4-years long SIRMIO project, started in November 2017, aims at realizing and 
demonstrating an innovative prototype system for precision small animal proton 
irradiation suitable for integration at existing clinical treatment facilities. Although the 
platform is still under development, the design of its main components has been largely 
completed and first devices are either in the process of being manufactured/tested or 
close to being ordered/constructed. The envisioned overall assembly is depicted in 
figure 6 for the two relevant workflows, which foresee pre-treatment transmission ion 
imaging (up), potentially complemented by US tumour visualization and co-registration, 
followed by dose delivery (down). The in-house developed holder is designed to 
guarantee sterile conditions between a portable laminar-flow biological safety cabinet, 
where the animals will be prepared after transportation from the animal facility, and the 
treatment site. Moreover, it has to guarantee stable positioning of the mouse, which will 
be moved with a precision rotational and translational stage during both the imaging and 
dose delivery process. Fine-tuning of the beamline design and related ordering of the 
components will follow the outcome of the ongoing treatment planning and beamline 
optimisation studies, identifying the ideal trade-off between the conflicting 
requirements of increased transmission (for faster irradiation and sufficient energy 
deposition rate for ionoacoustics) and small spot size. According to the current timeline, 
construction and first testing of the SIRMIO beamline is expected by the end of 2019, 
while integration of the different detector components is planned in the course of 2020. 
This schedule aims at enabling first proof-of-principle phantom experiments within the 
end of the project in fall 2021, prior to the deployment of the system for comparative in-
vivo studies of different biological endpoints after image-guided proton and photon 
small animal irradiation at the SIRMIO and SARRP platforms, respectively. This way, 
SIRMIO will provide new experimental insights into animal-based proton therapy 
research, holding a great potential to foster relevant advances in bench-to-bedside 
translational research beyond state-of-the-art. Future versions of the system are already 
envisioned to enable also beam scanning, to minimize the small animal movement and 
potentially enhance the treatment throughput. Although the first prototype is especially 
optimised on the basis of experimentally-benchmarked MC phase space information 
from a ProBeam facility [9], the design is flexible enough to accommodate (possibly 
with minor modifications) the low energy beam characteristics of different proton 
therapy facilities from different vendors. Hence, the proposed new platform is deemed 
suitable for wide deployment in the proton therapy community to enable innovative 
radiobiological research not possible with current infrastructures. 
Figure 6: Illustration of the SIRMIO configurations for pre-treatment imaging (a, top), 
using the clinically available (scanned) beam with the proposed single particle tracking 
imaging system, followed by image-guided dose delivery (b, bottom), with the dedicated 
beamline and detector instrumentation in place. 
 
Acknowledgments 
The authors would like to thank A.S. Savoia from Roma Tre University, Rome, Italy, T. 
Yamaya and his team from National Institute of Radiological Sciences, Chiba, Japan, A. 
Zoglauer from University of California, Berkeley, USA, E. Traneus and R. Nilsson 
from RaySearch Laboratories, Stockholm, Sweden, M. Hillbrand and D. Köpl from 
Rinecker Proton Therapy Center, Munich, Germany, F. Verhaegen from Maastro Clinic, 
Maastricht, The Netherlands, R. Hertenberger from LMU Munich, R. de Oliveira from 
CERN, Geneva, Switzerland, John Gordon from Pyramid Technical Consultants 
Europe, West Sussex, UK,  as well as M. Vidal and J. Herault from Centre Antoine 
Lacassagne, Nice, France, for their fruitful collaboration and several contributions to the 
project. M. Schillo and colleagues from Varian Medical Systems Particle Therapy 
GmbH, Troisdorf, Germany are acknowledged for useful technical discussions on the 
Rinecker Proton Therapy Center. 
 
Disclosure statement 
The LMU Medical Physics Department has a license and (planned) research 
collaboration agreement with the company RaySearch Laboratories AB for the -
RaySearch small animal treatment planning system, as well as a collaborative research 
agreement with the Department of Engineering of Roma Tre University.  
 
References 
[1] Baumann M, Krause M, Overgaard J et al. Radiation oncology in the era of 
precision medicine. Nat Rev Cancer 2016;16:234-49 
[2] Durante M. New challenges in high-energy particle radiobiology. Br J Rad 
2014;87:20130626 
[3] Verhaegen F, Granton P and Tryggestad E. Small animal radiotherapy research 
platforms. Phys Med Biol 2011;56:R55-R83 
[4] Parodi K, Mairani A, Brons S et al. Monte Carlo simulations to support start-up and 
treatment planning of scanned proton and carbon ion therapy at a synchrotron-based 
facility. Phys Med Biol 2012;57:3759-84 
[5] Mirandola A, Molinelli S, Vilches Freixas G et al. Dosimetric commissioning and 
quality assurance of scanned ion beams at the Italian National Centre for Oncological 
Hadrontherapy Med Phys 2015;42:5287 
[6] Ford E, Emery R, Huff D, Narayanan M, Schwartz J, Cao N, Meyer J, Rengan R, 
Zeng J, Sandison G, Laramore G, Mayr N. An image-guided precision proton radiation 
platform for preclinical in vivo research. Phys Med Biol 2017;62:43-58 
[7] Agostinelli S, Allison J, Amako KA, et al. Geant4 – a simulation toolkit. Nucl 
Instrum Methods Phys Res, Sect A 2003;506:250–303. 
[8] Borland M, elegant: A Flexible SDDS-Compliant Code for Accelerator Simulation, 
Advanced Photon Source LS-287, September 2000 
[9] Würl M, Englbrecht F, Parodi K, Hillbrand M. Dosimetric impact of the low-dose 
envelope of scanned proton beams at a ProBeam facility: comparison of measurements 
with TPS and MC calculations. Phys Med Biol 2016;61:958. 
[10] Telsemeyer J, Jäkel O, Martisıkova M. Quantitative carbon ion beam radiography 
and tomography with a flat-panel detector. Phys Med Biol 2012;57:7957e71 
[11] Ferrari A, Sala P R, Fassó A and Ranft J. FLUKA: a multi-particle transport code 
CERN Report CERN-2005-10 INFN/TC_05/11, SLAC-R-773. 2005 
[12] Böhlen T, Cerutti F, Chin M, Fassó A, Ferrari A, Ortega P, Mairani A, Sala P, 
Smirnov G and Vlachoudis V.The FLUKA code: developments and challenges for high 
energy and medical applications. Nucl Data Sheets 2014;120:211–214 
[13] Resch A F, Landry G, Kamp F, Cabal G, Belka C, Wilkens JJ, Parodi K and Dedes 
G. Quantification of the uncertainties of a biological model and their impact on variable 
RBE proton treatment plan optimisation. Phys Med 2017;36:91–102 
[14] Assmann W, Kellnberger S, Reinhardt S et al. Ionoacoustic characterization of the 
proton Bragg peak with submillimeter accuracy. Med Phys 2015;42:567 
[15] Parodi K. Vision 20/20: Positron emission tomography in radiation therapy 
planning, delivery, and monitoring. Med Phys 2015;42:7153 
[16] Nishikido F, Inadama N, Yoshida E et al. Four-layer DOI PET detectors using a 
multi-pixel photon counter array and the light sharing method. Nucl Instrum Methods 
Phys Res A 2013;729:755–761 
[17] Kurichiyanil N, Pinto M, Rösch T, et al. Design of an adaptable permanent-magnet 
quadrupole triplet for refocusing of energy degraded proton beams for small animal 
irradiation. Submitted to AAPM 2019 
[18] Würl M, Moskal I, Carriço M, et al. Feasibility study for small-animal proton 
radiography using passive energy variation and a single planar detector, 49. 
Jahrestagung der DGMP 2018, Nürnberg, Abstractband p.244 
[19] Meyer S, Bortfeldt J, Lämmer P, et al. Optimisation and Performance Evaluation of 
a Proton Computed Tomography System for Small Animal Imaging, accepted for oral 
presentation at PTCOG 2019 (to appear in IJPT) 
[20] Bortfeldt J, Lämmer P, Meyer S, et al. Development of a Time Projection Chamber 
for Ion Transmission Imaging, Poster at the 15th Vienna Conference on 
Instrumentation, 2019 
[21] Lascaud J, Lehrack S, Wieser HP, et al. Applicability of Capacitive 
Micromachined Ultrasonic Transducers for the detection of proton-induced 
thermoacoustic waves. Submitted to IEEE IUS 2019 
 
